Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Tirzepatide (Eli Lillys Mounjaro/Zepbound) is a dual GLP-1/GIP receptor agonist with four years of Phase 3 data, three FDA approvals, and a published cardiovascular outcomes trial
Since our inception in 2013, we have developed from our singular Miami clinic to becoming a worldwide brand, delivering safe and nutritionally effective IV drip therapies and booster shots
Similar to GIP, GLP-1 led to a notable suppression of the bone resorption marker CTX-1
This characteristic suggests the peptide works through regulatory mechanisms that plateau rather than dose-dependent stimulation that could run out of control
By enhancing mitochondrial function and fatty acid metabolism, it improves insulin signaling in muscle cells
US$ 27.81
US$ 21.52
US$ 28.68
